N-able, Inc. NABL 深 滬
已收盤 02-06 16:00:00 美东时间
5.61
+0.100
+1.81%
華盛通- 最 高5.75
- 今 開5.67
- 成交量 207.06万股
- 最 低 5.435
- 昨 收 5.51
- 總市值 10.45亿
- 52周最高 10.408
- 市盈率 靜 34.14
- 換手率 1.11%
- 52周最低 5.33
- 委 比 -77.31%
- 總股本 1.86亿
- 歷史最高 15.85
- 量 比 1.06
- 振 幅 5.72%
- 歷史最低 5.33
- 每 手 1
- 風險率 0.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
B. Riley Securities Initiates Coverage On N-able with Buy Rating, Announces Price Target of $10
B. Riley Securities analyst Erik Suppiger initiates coverage on N-able (NYSE:NABL) with a Buy rating and announces Price Target of $10.
01-23 18:54
Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period'
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
2025-12-19 03:38
N-able Empowers DoD Contractors with New Cybersecurity Tools for Stronger Business Resilience
N-able, Inc. (NYSE:NABL), a global software company delivering an end-to-end cyber resilience platform, today announced the public preview of a version of its N-able N-central unified endpoint management (UEM) solution
2025-11-18 19:09
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
N-able shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates. Also, the company raised its FY25 sales guidance above estimates.
N-able shares are trading higher after the company reported better-than-expecte...
2025-11-06 22:24
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
2025-08-11 09:43
N-Able shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, and raised its FY25 sales guidance above estimates.
N-Able shares are trading higher after the company reported better-than-expecte...
2025-08-07 21:12
N-able Sees Q3 Sales $127.000M-$128.000M vs $125.138M Est
N-able (NYSE:NABL) sees Q3 sales of $127.000 million-$128.000 million vs $125.138 million analyst estimate.
2025-08-07 19:03
